The ongoing opioid crisis, claiming over 70,000 lives annually in the U.S. according to the CDC’s 2023 data, presents a perplexing scenario where regulatory bodies, in their attempt to curb misuse, have inadvertently intensified challenges for health care providers and patients. The Centers for Disease Control and Prevention (CDC) issued its 2016 guideline for prescribing opioids for chronic pain, with revisions in 2022 to address misapplications, yet these efforts have fallen short and, in many cases, exacerbated the crisis. A 2021 study in JAMA found that while opioid prescribing rates dropped by 37 percent from 2014 to 2019, overdose deaths continued to rise, driven by illicit fentanyl, suggesting that restrictive policies have not effectively addressed the root causes.
In an effort to curtail opioid misuse, authorities have implemented stringent regulations, often described as excessively cautious—more Catholic than the Pope, as the saying goes. These measures have pushed health care providers and patients from the frying pan into the fire. For instance, the Drug Enforcement Administration (DEA) has intensified scrutiny, with a 2022 report from the American Medical Association (AMA) noting a 44 percent decrease in opioid prescriptions since 2011, yet this has coincided with increased barriers to legitimate pain management. State pharmacy boards, empowered to grant pharmacies autonomy to deny prescription fulfillment based on vague “comfort” criteria, often demand treatment plans adhering to arbitrary standards. This rigid framework disregards the nuanced expertise of physicians, as highlighted by Dr. Nora Volkow, director of the National Institute on Drug Abuse, who in a 2023 New England Journal of Medicine article emphasized that overly restrictive policies can undermine patient-centered care, turning constructive medicine into defensive medicine.
These regulations have also exacerbated shortages of pain medications. A 2024 report from the American Society of Health‑System Pharmacists noted supply chain disruptions for critical opioids like morphine, compounded by DEA‑imposed production quotas. This scarcity burdens physicians, who fear repercussions from governmental overreach. A 2022 survey by Pain Medicine found that 78 percent of pain specialists reported hesitancy to prescribe opioids due to fear of legal scrutiny, with 62 percent citing potential career risks. Dr. Daniel Carr, a pain management expert at Tufts University, stated in a 2023 Health Affairs interview, “Physicians are caught in a vise—balancing patient needs against the risk of regulatory punishment.” Consequently, patients with chronic pain, such as those with cancer or sickle cell disease, face significant barriers. A 2023 Journal of Pain study reported that 41 percent of chronic pain patients experienced reduced access to prescribed opioids, with some turning to illicit sources, contributing to a 20 percent rise in fentanyl‑related overdoses from 2020 to 2022, per CDC data.
The opioid crisis is further compounded by misdirected blame on physicians, stripping them of autonomy through excessive regulation. This web of rules creates chaos, diverting focus from the fundamental mission of patient well‑being. A 2024 AMA Journal of Ethics article noted that physicians face fines or license suspension for minor prescribing infractions, fostering a culture of fear. For example, a 2023 case in California saw a physician fined $50,000 for prescribing opioids to a terminal cancer patient without exhaustive documentation, illustrating how punitive measures exploit doctors, shifting their focus from healing to costly defense efforts.
To break this vicious cycle, re‑establishing trust in physicians is critical. Experts like Dr. Sally Satel, a psychiatrist and addiction specialist, argues in a 2024 Atlantic op‑ed that “Empowering physicians with evidence‑based flexibility, rather than blanket restrictions, is essential to address both pain and addiction.” A collaborative approach, as recommended by a 2023 National Academy of Medicine report, would involve integrating physician input into policymaking and revising CDC guidelines to prioritize individualized care. By fostering an environment that respects clinical expertise, we can refocus efforts on alleviating patient suffering—the central mission of health care—while tackling the opioid crisis more effectively.
Kayvan Haddadan is a physiatrist and pain management physician, and president and medical director of Advanced Pain Diagnostic & Solutions, a multidisciplinary pain management practice in California that he founded in 2012. A physician and surgeon licensed by the Medical Board of California, he is double board-certified in pain medicine and physical medicine and rehabilitation. He is also certified in controlled substance registration through the DEA and serves as a qualified medical examiner through California’s Department of Industrial Relations Division of Workers’ Compensation.
Dr. Haddadan earned his Bachelor of Science degree from the College of Alborz in Tehran, Iran, and his medical degree from Shahid Beheshti University of Medical Sciences. He later received his Educational Commission for Foreign Medical Graduates certification in Philadelphia, completed an internship in medical surgery at Loyola University Medical Center’s Stritch School of Medicine in Illinois, and finished his residency in physical medicine and rehabilitation at the same institution. He completed his fellowship in pain medicine at California Pacific Medical Center’s Pacific Pain Treatment Center and also trained in medical acupuncture for physicians at the University of California, Los Angeles David Geffen School of Medicine.
Dr. Haddadan has contributed to 29 research publications across multiple specialties, including pain management, cardiology, pulmonology, endocrinology, gastroenterology, and infectious disease. His work has examined topics such as hyperlipidemia in high cardiovascular risk patients, hyperuricemia and gout management, type 2 diabetes and hypertension, chronic obstructive pulmonary disease and asthma therapies, influenza treatment, irritable bowel syndrome, and opioid related complications in chronic pain care. His research has also included clinical outcome studies in spinal cord stimulation and award-winning presentations on neuropathic pain management and neuromuscular disorders.
